Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows
Agreement supports the identification of patients eligible for Alzheimer's disease biomarker testing through Tempus Next and enables neurologists to order LucentAD® Complete on Tempus' clinical ordering platform
Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ:QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer's disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer's disease blood-based biomarker testing, with the LucentAD® Complete multi-biomarker blood test becoming available for neurologists to order on the Tempus clinical ordering platform.
More than 7 million Americans are living with Alzheimer's disease today, yet only a small fraction are evaluated for eligibility for approved treatments. The collaboration aims to narrow that gap by embedding clinical guideline-directed identification and blood-based biomarker testing options directly into clinical decision-making workflows used by neurologists.
"This collaboration represents an important step toward ensuring blood-based Alzheimer's biomarker testing becomes part of routine clinical practice – without placing additional burden on providers," said Everett Cunningham, CEO of Quanterix. "By working with Tempus to integrate LucentAD Complete into the clinical ordering workflow, we are helping reduce barriers to access and equipping neurologists with a more seamless, non-invasive approach to identifying amyloid-positive patients who may benefit from approved therapies. As we look to advance precision health through high-sensitivity biomarker innovation, collaborations that streamline the diagnostic journey are essential to support earlier, more confident clinical decisions."
Tempus Next is an AI-enabled care pathway intelligence platform that identifies care gaps and equips providers with actionable insights consistent with clinical guidelines at the point of care. While the Tempus Next Care Gap Program helps identify patients who may benefit from biomarker testing based on established clinical guidelines, clinicians have the option to order LucentAD Complete through existing EHR integrations.
About Lucent Diagnostics
Lucent Diagnostics, a commercial brand of Quanterix, was created in 2023 to deliver revolutionary tools that aid in the earlier detection of cognitive disease. Powered by the ultra-sensitive Simoa® technology, Lucent Diagnostics bridges the gap between research and clinical use by offering products and services designed specifically to meet the separate needs of institutions and healthcare providers. With more than a decade of proven success within the neurology research space, supported by thousands of publications and partnerships, Quanterix aims to directly impact the landscape of cognitive disease through its commercial brand, Lucent Diagnostics. For more information, please visit www.LucentDiagnostics.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260506938892/en/
Quanterix Media Contact:
media@quanterix.com
Investor Relations Contact:
Joshua Young
(508) 846-3327
jyoung@quanterix.com
